Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs docetaxel phase 2–3 trial in Japan
jRCT2080222306Phase 3Completed
- Start
- Nov 2013
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab in cancer (2 arms). Started Nov 2013; status: completed.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080222306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222306.